Ikarian Capital’s Solid Biosciences SLDB Stock Holding History

Ikarian Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$429K	Sell	42,956 -221,453	-84%	-$1.68M	0.05%	124
2026 Q1	$1.9M	Buy	264,409 +104,000	+65%	+$668K	0.15%	100
2025 Q4	$905K	Sell	160,409 -16,281	-9%	-$88.2K	0.07%	128
2025 Q3	$1.09M	Buy	+176,690	New	+$1.03M	0.11%	117
2025 Q2	–	Sell	-230,000	Closed	-$851K	–	182
2025 Q1	$851K	Buy	+230,000	New	+$985K	0.1%	101
2022 Q2	–	Sell	-34,744	Closed	-$625K	–	196
2022 Q1	$625K	Hold	34,744	–	–	0.08%	118
2021 Q4	$911K	Hold	34,744	–	–	0.14%	103
2021 Q3	$1.25M	Sell	34,744 -10,301	-23%	-$437K	0.09%	150
2021 Q2	$2.47M	Buy	45,045 +43,471	+2,762%	+$2.87M	0.2%	119
2021 Q1	$131K	Sell	1,574 -50,960	-97%	-$5.64M	﹤0.01%	279
2020 Q4	$5.97M	Hold	52,534	–	–	0.26%	83
2020 Q3	$1.6M	Hold	52,534	–	–	0.12%	121
2020 Q2	$2.31M	Buy	52,534 +16,597	+46%	+$689K	0.18%	102
2020 Q1	$1.29M	Buy	+35,937	New	+$1.78M	0.1%	112

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital's SLDB Position: Q2 2026 in Review

Ikarian Capital reduced its Solid Biosciences (SLDB) stake by 84% in Q2 2026, selling an estimated $1.68M and leaving 42,956 shares worth $429K. The position accounts for 0.05% of the portfolio, ranked #124.

Ikarian Capital first reported a position in SLDB in Q1 2020 and has held it in 14 quarters since. The position peaked at $5.97M in Q4 2020. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Ikarian Capital held 42,956 shares of Solid Biosciences worth $429K as of Q2 2026.
Ikarian Capital sold 221,453 Solid Biosciences shares in Q2 2026, an estimated $1.68M.
Solid Biosciences made up 0.05% of Ikarian Capital's portfolio in Q2 2026, its #124 holding.
Ikarian Capital first reported a position in Solid Biosciences in Q1 2020 and has held it in 14 quarters since.
Ikarian Capital's Solid Biosciences position peaked at $5.97M in Q4 2020.
156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.